Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; purified water; hydrochloric acid; caldiamide sodium hydrate - other conditions: do not freeze. omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood brain barrier or abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularlity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: caldiamide sodium hydrate; sodium hydroxide; water for injections; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection - excipient ingredients: water for injections; caldiamide sodium hydrate; sodium hydroxide; hydrochloric acid - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - gadodiamide, quantity: 287 mg/ml - injection, solution - excipient ingredients: caldiamide sodium hydrate; hydrochloric acid; water for injections; sodium hydroxide - omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance imaging of intracranial and spinal lesions where there is an abnormal blood-brain barrier of abnormal vascularity. indications as at 10 december 1999: omniscan is indicated for use in adults and children from 6 months of age for enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity and whole body imaging. indications as at 25 june 2003: omniscan is indicated for: 1) use in adults and children, including infants and neonates less than 6 months of age for the enhancement of magnetic resonance images of intracranial and spinal lesions where there is an abnormal blood-brain barrier or abnormal vascularity, and; 2) whole body imaging for adults and children over 6 months of age.

Izrael - angličtina - Ministry of Health

a.m.i. medical technologies limited, israel - adapalene; benzoyl peroxide - gel - benzoyl peroxide 25 mg/g; adapalene 1 mg/g - benzoyl peroxide - cutaneous treatment of acne vulgaris when comedones, papules and pustules are present.

Izrael - angličtina - Ministry of Health

eldan electronic instruments co ltd - ioflupane - solution for injection - ioflupane 74 mbq/ml - iodine ioflupane (123i) - other dopaminergic agents - datscan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum: - in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson's disease multiple system atrophy and progressive supranuclear palsy. - datscan is unable to discriminate between parkinson's disease multiple system atrophy and progressive supranuclear palsy. - in adult patients to help differentiate probable dementia with lewy bodies from alzheimer's disease. datscan is unable to discriminate between dementia with lewy bodies and parkinson's disease dementia

Evropská unie - angličtina - EMA (European Medicines Agency)

ge healthcare as - flutemetamol (18f) - radionuclide imaging; alzheimer disease - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.vizamyl is a radiopharmaceutical medicinal product indicated for positron emission tomography (pet) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for alzheimer’s disease (ad) and other causes of cognitive impairment. vizamyl should be used in conjunction with a clinical evaluation.a negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of ad.

Evropská unie - angličtina - EMA (European Medicines Agency)

eli lilly nederland b.v. - florbetapir (18f) - radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.amyvid is a radiopharmaceutical indicated for positron emission tomography (pet) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for alzheimer’s disease (ad) and other causes of cognitive impairment. amyvid should be used in conjunction with a clinical evaluation.a negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of ad.

Evropská unie - angličtina - EMA (European Medicines Agency)

cis bio international  - besilesomab - osteomyelitis; radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. scintimun should not be used for the diagnosis of diabetic foot infection.

Evropská unie - angličtina - EMA (European Medicines Agency)

blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - diagnostic radiopharmaceuticals - this medicinal product is for diagnostic use only.axumin is indicated for positron emission tomography (pet) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (psa) levels after primary curative treatment.